Aurobindo Pharma is currently trading at Rs. 678.00, up by 4.55 points or 0.68% from its previous closing of Rs. 673.45 on the BSE.
The scrip opened at Rs. 683.90 and has touched a high and low of Rs. 688.95 and Rs. 672.75 respectively. So far 74090 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 895.00 on 06-Oct-2016 and a 52 week low of Rs. 582.00 on 25-Feb-2016.
Last one week high and low of the scrip stood at Rs. 722.00 and Rs. 665.35 respectively. The current market cap of the company is Rs. 39671.57 crore.
The promoters holding in the company stood at 53.79%, while institutions and non-institutions held 34.39% and 11.82% respectively.
The US Food and Drug Administration (USFDA) has reportedly issued Form 483 observations against Unit I of Aurobindo Pharma in Hyderabad, India. The plant is used for manufacturing of active pharmaceutical ingredients (APIs), which contribute little over 20% of the company's total revenues.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |